Novavax (NVAX)

Executive Summary

Novavax is a biotechnology company specializing in protein-based vaccines using its recombinant nanoparticle technology. Its flagship product, NVX-CoV2373, is a COVID-19 vaccine authorized in multiple countries, but commercial uptake has been limited due to intense competition from mRNA vaccines. The company is pivoting toward combination vaccines (e.g., COVID-19/influenza) and next-generation COVID boosters to address waning immunity. As of mid-2026, Novavax has stabilized its finances through partnerships, including a licensing deal with Sanofi for COVID-19 and flu vaccines. The pipeline also includes an RSV vaccine candidate in Phase 2 and an influenza vaccine (NanoFlu) in Phase 2. Key near-term events include potential FDA authorization of an updated COVID-19 vaccine for the fall 2026 season and Phase 2 data readouts for the combo vaccine. However, Novavax faces significant challenges: sustained revenue dependence on COVID-19 vaccine sales, execution risk in clinical trials, and competition from mRNA and adjuvanted vaccines. The company's success hinges on differentiating its protein-based platform through improved durability and broader protection.

Upcoming Catalysts (preview)

• Q3 2026FDA Authorization of Updated COVID-19 Vaccine for Fall 2026 Season70% success
• Q1 2027Phase 2 Data Readout for COVID-19/Influenza Combination Vaccine50% success
• H2 2026RSV Vaccine Phase 2/3 Enrollment Completion or Early Data40% success